January 2022 | Targeted Therapies in Oncology

Adding Ibrutinib Improves the Efficacy of Liso-Cel in R/R CLL

January 28, 2022

Clinical Articles

Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.

Longer Follow-Up Shows Improved DFS With Nivolumab in MIUC

January 26, 2022

Clinical Articles

According to Matthew Galsky, MD, results from the CheckMate-274 clinical trial support adjuvant nivolumab as a standard of care for patients with high-risk muscle-invasive urothelial cancer after radical resection.

Immunotherapy Sparks Excitement for New Cervical Cancer Treatments

January 25, 2022

Clinical Articles

Immunotherapy has especially demonstrated broad activity in cervical cancer, fueling development in this area and providing further signs of hope for new treatment options to come into the landscape with greater efficacy and manageable safety profiles.